Minimal Residual Disease Status as a Surrogate Endpoint for ... - PubMed
A meta-analysis evaluated minimal residual disease (MRD) status as a surrogate for progression-free survival (PFS) in newly diagnosed multiple myeloma (NDMM). Analyzing 3283 patients across six studies, MRD negativity rates varied (0.06-0.70), showing strong correlation between MRD-negative response and PFS, supporting MRD as a valid PFS surrogate in NDMM.
Reference News
Minimal Residual Disease Status as a Surrogate Endpoint for ... - PubMed
A meta-analysis evaluated minimal residual disease (MRD) status as a surrogate for progression-free survival (PFS) in newly diagnosed multiple myeloma (NDMM). Analyzing 3283 patients across six studies, MRD negativity rates varied (0.06-0.70), showing strong correlation between MRD-negative response and PFS, supporting MRD as a valid PFS surrogate in NDMM.